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ABSTRACT 
Brain targeting is a difficult task due to various factors; those factors can restricts the entry of drugs into the brain, in present study 
polymer-lipid hybrid nanoparticles were prepared for targeting carbamazepine into the brain through the intranasal route. Five 
formulations were successfully prepared using chitosan, stearic acid and glyceryl mono stearate in different ratio. The particles size 
were found between 78.88-790nm, the poly dispersibility index were found in the range of 0.273-0.531, the zeta potential were 
found to be -7.1, -11.6, 22.3 for HN1, HN2, HN3 respectively and for formulation HN4 and HN5 it was found as +12.1 and +22.3. 
The entrapment efficiency of all the formulations was found between 62.66-88.31%, the in-vitro releases were found in the range of 
40-72%. The in-vivo studies were performed on Wister rats. Formulation HN5 containing higher conc. of chitosan has shown high 
drug targeting efficiency. The lipid-polymer hybrid nanoparticles have shown the possibility of targeting the brain through intranasal 
delivery. 
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INTRODUCTION  
Carbamazepine is a well-known drug for treating 
epileptic seizures; it is a first-line drug for the treatment 
of partial seizures 
1, 2
, with or without second 
generalization, and generalized tonic-clonic seizures. 
The t1/2 of carbamazepine is 25-85 hr after a single dose, 
if dose is repeated for long time, auto-induction takes 
place in liver, which results in the fluctuations in the 
plasma conc. this precipitates various unwanted effects 
like neuromuscular disorder, cardiovascular, 
gastrointestinal effects and some serious pathological 
conditions like skin allergies, dysfunction of kidney and 
liver 
3,4
 to overcome these side effects drug should be 
targeted directly into brain, which is a very tough job 
because of the anatomy and functionality of a 
specialized barrier, the blood brain barrier (BBB), the 
capillary endothelial cells which separate the blood with 
underlying brain cell, it does not permit the drug or other 
foreign material to travel into brain from systemic 
circulation 
1, 5
. The bioavailability of the particles is 
found to be the reason for the Nanomedicine to gain 
precedence.
6
 In last 10-15 years, various techniques have 
been employed to deliver drug directly into the brain by 
penetrating the drug through the BBB. There are various 
alternative routes for drug administrations are practiced 
now; intranasal drug delivery has drawn the attention of 
researcher for development of novel drug delivery 
5, 7
. 
Intranasal drug delivery seems good alternative to the 
injectables for targeting the directly into blood stream or 
targeting the brain 
8, 9
. Intranasal route prevents the first 
pass effect and enzymatic degradation in stomach or 
intestine, intranasal delivery shows quick onset of 
action, it is self medicable and can be used in emergency 
conditions 
10
. It has few restrictions like the particle size, 
molecular weight and low residence time due to rapid 
Arya et al                                                                                                            Journal of Drug Delivery & Therapeutics. 2017; 7(4):129-136 
ISSN: 2250-1177                                                                              [130]                                                                            CODEN (USA): JDDTAO 
mucociilary clearance of drugs in the nasal cavity.
11, 12, 13
 
These  problems can be reduced by using small carriers 
like nanoparticles made up of mucoadhesive polymers. 
These nanoparticles may be used to deliver the drug 
directly into brain via intranasal administration, because 
of their nanosize and mucoadhesive characteristics 
1
. 
Polymer–lipid hybrid nanoparticles are new age 
nanoparticles which are composed of lipid and polymer. 
Polymer–lipid hybrid nanoparticles are designed to take 
the advantage of polymeric as well as lipid nanoparticles 
in a single particle
14
. Jian L et al., 2010
15
 developed 
polymer lipid hybrid nanoparticles containing non-viral 
gene vector for high transfection efficiency and low 
toxicity towards normal cells with long circulatory time. 
Wang J et al., 2013
16
 prepared polymer–lipid hybrid 
nanoparticles for targeting vinculin intracellularlly. In 
Polymer–lipid hybrid nanoparticles, there two different 
types of polymer (hydrophilic and lipophilic polymer) 
are used; therefore a poor water soluble therapeutic 
agent as well as highly water soluble therapeutic agent 
can be loaded with high drug loading. The hybrid 
nanoparticles have good drug loading efficiency. In 
hybrid nanoparticles the hydrophilic polymeric layer is 
covered by a lipophilic envelop. Hybrid nanoparticles 
can also be used for diagnostic purpose 
17
, the polymer-
lipid hybrid nanoparticles have many advantage over the 
simple polymeric nanoparticles and liposomes. Polymer-
lipid hybrid nanoparticles can be used in the targeting 
organs, delivering the genetic materials to the target site 
18
. The hybrid nanoparticles have the property to adhere 
with other substrate; it can be easily conjugated with 
antibody 
19
. In our previous work, given elsewhere, we 
have studied the carbamazepine loaded chitosan 
nanoparticles, for targeting the brain from intranasal 
route; the study shows there is a possibility to target the 
brain from nasal route 
1
. 
MATERIAL AND METHOD 
Material    
Chitosan was obtained as a gift sample from Central 
Institute of Fisheries Technology, Kocchi, 
Carbamazepine was purchased from Sigma Alderich 
Mumbai, Glyceryl mono stearate, Stearic acid, Tween-
80 was purchased from CDH, Mumbai, Dialysis 
membrane-70 was purchased from Hi-Media, Mumbai. 
All other chemicals and solvents used in the study were 
of analytical or HPLC grade. 
Method 
Polymer-lipid Hybrid nanoparticles containing 
carbamazepine were prepared by microemulsification 
followed by ultrasonication method. The lipids (oil 
phase) were dispersed in n-butanol, and then heated at 
10ºC above the melting point of the lipid. 100mg drug 
was dissolved in molten lipid. A 50ml aqueous solution 
of chitosan was separately prepared in 0.5% v/v acetic 
acid and 1% Tween-80 and the heated to 70-80ºC. The 
oil phase was added into hot aqueous phase with 
continuous stirring for 30min to prepare microemulsion. 
The organic solvent was allowed to evaporate by 
continuous stirring and heating on mechanical stirrer. 
The resultant microemulsion was finally poured into 
200ml of ice cold water (2-3ºC). The dispersion was 
then sonicated by ultrasonic probe sonicator for 9min (3 
cycles of 3min) and off time was 10sec. The resultant 
dispersion was then centrifuged at 10,000 RPM for 
15min. The Polymer-lipid hybrid nanoparticles 
dispersion was collected and lyophilized. 
 
Table 1: Showing all formulations  
 
Fourier Transform Infrared Spectroscopy 
20
 
The FTIR spectra were obtained by FTIR 
spectrophotometer (FTIR-8400SCE, Shimadzu 
Corporation). The binary mixture of previously dried 
powder samples of carbamazepine and excipients were 
mixed with dry potassium bromide and pellets were 
made with the help of hydraulic press and scanned 
within the range of 4000 to 400 cm
−1
. 
Particle Size and Surface Morphology 
20, 21
 
The particle size and polydispersity index of 
manufactured carbamazepine containing polymer lipid 
hybrid nanoparticles was determined with the help of 
Photon Correlation Spectroscopy using Zetasizer. 3 
reading for each sample were recorded. The surface 
morphology was determined with the help of 
Transmission Electron Microscopy (TEM). 
Zeta Potential: 
20, 21
 
Zeta potential was measured by using Zetasizer 
(Malvern, Ver. 6.01). The hybrid nanoparticles were 
diluted 10 times with distilled water and analyzed. 
Drug Entrapment Efficiency 
1
 
The entrapment efficiency can be calculated by 
dissolving 25mg drug loaded nanoparticles in 10ml 
methanol and kept for overnight, then filtered by 0.2µ 
membrane filter and then analyzed by UV 
spectrophotometer at 280.4 nm.  
        
                                                 
                         
          eq. 01 
Formulation Ingredient 
Carbamazepine Chitosan GMS Stearic acid Tween-80(ml) 
H1 100 100 50 50 1 
H2 100 100 100 100 1 
H3 100 100 150 150 1 
H4 100 200 50 50 1 
H5 100 200 50 50 1 
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Where, Initial drug is the mass of initial drug used for 
the assay. Free drug is the mass of free drug detected in 
the supernatant after centrifugation of the aqueous 
dispersion. 
In-Vitro Drug Release Study Nanoparticles 
1 
The in-vitro drug release was carried out on Franz 
diffusion cell using the dialysis membrane which was 
mounted over receptor compartment. Phosphate buffer 
of pH 5.5 was used as the dissolution medium and the 
temperature of medium was maintained 37°C±0.5°C. 
The stirring was done at 100 rpm using a magnetic bar. 
5ml of dissolution medium was withdrawn at 0.5, 1, 2, 3 
to 9hr, which was replaced with the 5ml fresh medium 
for maintaining the sink condition. The amount of drug 
release from the nanoparticles was analyzed by UV 
spectrophotometer at 280.4 nm. 
In-Vitro Drug Release Kinetics 
22, 23 
The data obtained from in-vitro drug release were fitted 
into mathematical models to understand the drug release 
mechanism, the release data were evaluated with the 
different kinetics models like zero-order, first-order, 
Korsmeyer-Peppas and Higuchi using Kinet DS 3 rev 
2010.  
In-Vivo study on Rats 
1
, 
2
 
The in-vivo experiments on rat were performed at 
Deshpande Lab Bhopal, India. All animal studies were 
performed according to CPCSEA. The CPCSEA/IAEC 
approval No. IAEC /DL /2015/RK/012. 54 Male Wister 
rats were used with a weight range of 200-330gm. The 
animals were housed in standard cage, in a light 
controlled room (14:10hr. light dark/light cycle) and 
temperature controlled 20±2
0
C and 50±5% RH, with a 
proper feeding condition. The food was withdrawn 24hr. 
before experiment.  
Preparation of Drug solution for i.v. Administration 
1
, 
2, 4
 
The i.v. solution of drug was prepared by dissolving the 
drug in a mixture of propylene glycol, physiological 
saline (0.9%NaCl)-ethanol in a ratio of 5:3:2 to make a 
final conc. of 1mg per ml.   
Intranasal and i.v. administration 
1
, 
2, 4 
 
The rats anaesthetized by ketamine (100mg/ kg) and 
xylazine (10mg/kg) mixture given by i.p. and the 
temperature of room were maintained warm. The i.v. 
solution of drug containing dose of 1mg/kg was 
administered by injection on lateral tail vein. The hybrid 
nanoparticles were administered at a dose equivalent to 
1mg/kg to rat. The rat was placed on one side and the 
formulation was instilled using a polyurethane tube 
attached to a syringe. The tube inserted to 10mm deep 
into one of the nares, to deliver the formulation to roof 
of the nasal cavity. The rats were divided into two 
groups, group 1 containing 18 animals which received 
the drug by i.v. administration and group 2 containing 36 
animals received polymer-lipid hybrid nanoparticles. At 
a set time interval (5, 15,30,45,60,120 min) after dosing 
3 animal per time point were sacrificed by cervical 
dislocation then decapitated. The blood was then 
immediately collected in tube containing heparin. The 
brain was removed and weighed. The blood samples 
were centrifuged at 4
0
C at 4000rpm for 10min. the 
plasma were stored at -30
0
C for further analysis. The 
brain was homogenized with 0.1M sod phosphate buffer 
pH5.0 (4ml/gm) of tissue. The Teflon pestle tissue 
homogenizer was used. Tissue homogenate was then 
centrifuged at 4000rpm for 15min at 4
0
C and the 
supernatant was then kept at -30
0
C for further analysis.        
Drug Analysis: 
1
 
The analysis of the Carbamazepine was performed by 
using HPLC with variable wavelength UV detector 
(SPD- 20A) operated at 280.4nm. Column used in 
HPLC is of 250mm x 4.6mm 5µ (Enable, C18G, 
150mmx4.6mm, 5µ is suitable) with a flow rate of 1 
ml/min (isocratic). The mobile phase consists of a blend 
of methanol /phosphate buffer, (80:20) v/v. The amount 
of carbamazepine in serum and brain was expressed as 
ng/ml serum. 
Pharmacokinetic analysis 
1
, 
2, 4 
 
The peak plasma conc. Cmax of drug was directly 
observed from plasma or brain and the time to reach 
Cmax (Tmax) was directly estimated from the data received 
by experiments, other Pharmacokinetic parameter were 
calculated based on the SEM (n=3) at each time point by 
a non-compartment pharmacokinetics analysis. The 
pharmacokinetics parameters were evaluated were the 
Area Under curve AUC from t0 to the last quantifiable 
conc. tlast by linear trapezoidal rule. For determining the 
brain targeting efficiency of intranasal drug delivery the 
drug targeting efficiency (DTE) index was calculated. It 
is a ratio of nasal and i.v. 
1
, 
2, 4
 
                                                    
    
                                  
                        
             (eq. 2) 
Where AUCbrainand AUCplasma are the area under the 
drug conc. time curve for brain and plasma after 
intranasal and i.v. application. For the good drug 
targeting the DTE should be>1. The data were expressed 
as SEM, a comparison was done between i.v. and 
intranasal delivery, single unpaired one tail ANOVA 
was used, difference was considered significant for a p- 
value p<0.05.  
RESULT AND DISCUSSION 
Fourier Transform Infrared Spectroscopy 
The FTIR spectra of a-carbamazepine b-physical 
mixture of carbamazepine, chitosan, glyceryl mono 
stearate and stearic acid are given in fig.1. The spectra 
showed characteristic absorption band at 3464 (NH 
Stretching of NH2) remain unchanged 3464, 3154 
(Aromatic CH stretching) slightly changed to 3159, 
1674 (C=O stretching of CO NH2) slightly changed to 
1677, and 1488 (C=C ring stretching) remain unchanged 
as 1488. The FTIR spectra of carbamazepine revealed 
that there was no chemical interaction between 
carbamazepine and the excipients.  
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Figure 1: FTIR spectra of a-carbamazepine, b- carbamazepine + stearic acid + chitosan + glycerylmonosterate 
 
Particles Size and Morphology  
The result of particles size and polydispersibility 
indexes (PDI) of prepared nanoparticles are given in 
table 2. The particles size ranging from 78.88 to 790nm. 
Formulation HN1 contains chitosan and lipid in equal 
amount, a hazy preparation with a size of 790nm was 
found. In this study, it was observed that, the conc. of 
lipid influences the size of nanoparticles, on increasing 
the conc. of lipids, the particle size was decreased and 
PDI was increased and then on increasing the conc. of 
lipid again, the particle size was increased from 87.88 to 
125nm (formulation HN2 and HN3). The conc. of 
chitosan also influences the particles size, as the 
chitosan conc. was increased the particle size of the 
nanoparticles also increased. 
The TEM study was done to get surface morphology of 
nanoparticles. The surface of nanoparticles was found 
rough and somewhat spherical (fig. 2.) 
 
 
Figure 2: Transmission Electron Microscopic photograph of a-formulation HN2, b-formulation HN4 Zeta potential 
Zeta potential  
The zeta potential ranged from -7.1, -11.6, and 22.3 for 
HN1, HN2, HN3, for HN4 and HN5 zeta potential value 
were found as +12.1 and +22.3 (table -2) 
Percentage Entrapment Efficiency 
The percentage entrapment efficiency was found to be in 
the range of 62.66-88.31% (table- 2). The conc. of 
polymer and lipid influences the entrapment efficiency,  
the study reveals that, initially in case of HN1 as the 
lipid and chitosan conc. were equal the entrapment 
efficiency was found to be 62.66% and on increasing the 
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conc. of lipid in formulation HN2, the entrapment 
efficiency was increased to 85.22%, the then it was 
decreased to 78.45% in formulation HN3, this is due to 
the formation of a hard and thick layer of lipid, on 
increasing the conc. of lipid quick quenching of lipid 
takes place which forms a hard and thick layer, therefore 
the drug could not penetrate into the lipid layer. But in 
case of HN4 and HN5 as the conc. of chitosan increased 
the entrapment efficiency increases again to 86.51%-
88.31%.
 
Table 2: Results of Particle size, PDI, Zeta potential, Drug content, entrapment efficiency 
 
 In-Vitro Drug Release: 
The in-vitro release was carried out for 9hr in buffer pH 
5.5, it was found to be in the range of 40- 75%. The 
observation revealed that formulation HN1, HN4 and 
HN5 shows the initial burst release of 28-34% in first 
30min and then released slowly, the lipid conc. on 
increasing lipid conc. the drug release was retarded, as in 
case of formulation HN1, HN2 and HN3, due to the 
formation of a thick layer. But when the chitosan conc. 
increased the drug release also increased in case of 
formulation HN4 and HN5. 
 
Figure 3: Drug release profile of all Formulation in 
Phosphate buffer of pH 5.5 
The formulation HN5 has shown slow release than HN4 
because higher conc. of chitosan retards the release rate 
after 45min. because the polymer forms gel after 
swelling which hinder the release rate. In case of 
formulation HN1 the lipid and chitosan conc. is equal, 
the release was found to be 61.3. In case of HN2 and 
HN3 where the lipid conc. is more than HN1, the drug 
release decreased on increasing the conc. of lipid. A 
significant difference p>0.05(p=0.000256) was found. 
The formulations HN4 and HN5 have higher conc. of 
chitosan, a significant difference p<0.05(0.0335) was 
found in release rate of HN4 and HN5, which shows, as 
the conc. of chitosan increases the drug release was 
decreased. 
Kinetic modelling 
All the five preparations were evaluated for drug release 
kinetics using Kinet DS 3 rev 2010 to know the best fit 
kinetic model. The drug release of formulation HN1 
followed the Korsmeyer Peppas release pattern; this is 
due the presence of both chitosan polymer and lipid in 
same ratio. The drug release was solely affected by 
hydrophilic polymer chitosan, this expression tells that 
drug release follows Korsmeyer model with non-Fickian 
diffusion super class II (0.45 < n< 0 8.9), the fickian 
case-II transport mechanism associated with formation 
of water soluble glassy polymer and dissolution of lipid 
matrix. The drug release from formulation HN2 and 
HN3 best fit into the Higuchi model, the drug release 
depended on porosity and tortuosity of lipid matrix, the 
drug release decreased on increasing the lipid content 
because the porosity of lipid matrix was decreased.  
The drug release from formulation HN4 and HN5 best 
fit into the Korsmeyer-Peppas model. This shows the 
drug release was controlled by higher conc. of 
hydrophilic polymer chitosan, the release pattern of both 
formulation followed super class II where 0.45<n<0.89 
case II.  
 
Table 3: Release kinetic parameters of polymer lipid hybrid nanoparticles 
Formulation  Zero order First order Korsmeyer Peppas Higuchi 
 r 
2
 K r 
2
 K r 
2
 K r 
2
 K 
HN1 0.9969 0.5734 0.9968 -0.0005 0.9969 0.5734 0.9933 0.027 
HN2 0.9272 0.0009 0.9733 -0.0009 0.992 0.5814 0.994 0.0219 
HN3 0.8904 0.0008 0.9733 -0.0009 0.986 0.556 0.9948 0.0204 
HN4 0.9163 0.0011 0.9846 -0.0006 0.9899 0.5067 0.9921 0.0311 
HN5 0.8498 0.001 0.9733 -0.0009 0.9879 0.3878 0.9868 0.0267 
 
S.No Formulation  Particle size (nm) PDI Zeta potential (mV) % entrapment efficiency  
1 HN1 780±1.912 0.531±0.317     -7.1 62.66 
2 HN2 78.88±1.21 0.383±0.256     -11.6 85.22 
3 HN3 135±2.391 0.632±0.216     -22.3 78.45 
4 HN4 228±2.532 0.273±0.225     +12.1 86.51 
5 HN5 250±2.390 0.321±0.214     +17.3     88.31 
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Formulation HN2 contains lipid and chitosan in a ratio 
of 2:1 and HN4 contains lipid and chitosan in a ratio of 
1:2 both formulations were selected to understand the 
behavior and effect of polymers on the biodistribution of 
drug into brain or plasma from intranasal route. All 
selected formulation HN2 and HN4 was further 
evaluated for pharmacokinetics studies.  
Pharmacokinetics analysis of i.v. intranasally applied 
hybrid nanoparticles HN2 and HN4  
Fig:4 shows the drug conc. in plasma and brain after i.v. 
administration, the peak plasma conc.(Cmax) was found 
to be 1199ng which was achieved in plasma in first 5min 
and in brain the Cmax was achieved in 30min.The Cmax in 
brain was found to be 1357ng. Initially a higher conc. of 
drug was achieved in plasma then gradually a decline 
was seen in plasma conc. whereas the drug conc. in 
brain was increased slowly, this increment of drug conc. 
in brain after some time because the drug goes into brain 
from systemic circulation. The ratio of AUC (Brain) and 
AUC (Plasma) was found as 0.7144, this depicts, 
carbamazepine distributed into brain (target) and plasma 
(non-target) slight equally. This study also revealed that 
the drug initially achieve high conc. in plasma, this can 
lead to side effects. 
 
 
Figure 4: Showing plasma and brain concentration- time profile of carbamazepine after intravenous administration n=3 
SEM unpaired ANOVA, ** represents a significant difference, p<0.05 
 
 
Figure 5: Showing the plasma brain profile of formulation HN2 the conc. of drug ng/ml in the plasma and brain after 
intranasal administration of formulation n=3 SEM unpaired ANOVA, ** represents a significant difference, p<0.05. 
 
Figure 5 shows the drug conc. in plasma and brain after 
intranasal administration of hybrid nanoparticles HN2, 
The Cmax was found to be 2730ng in brain, which was 
achieved in first 5min but in plasma the Cmax was 
achieved in 45min and the Cmax was found to be 1223ng. 
The drug conc. in brain declined slowly. The drug conc. 
in plasma increases slowly and achieved Cmax then the 
conc. falls suddenly. This shows almost a 2-time 
increase in Cmax was found in brain than plasma. In all 
time points a significant difference was found in drug 
conc. in plasma and brain, The AUC(Brain) and 
AUC(Plasma) ratio was found as 1.881, this represents, that 
the high distribution of drug into brain than plasma can 
be achieved with HN2 nanoparticles. It shows hybrid 
nanoparticles target the brain more, rather than plasma. 
In formulation HN2 the chitosan polymer increases the 
residence time of the formulation when administered 
nasally. The brain targeting efficiency DTE was found 
to be 2.566. This shows hybrid nanoparticles have a 
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higher brain targeting efficiency than i.v. administration. 
The results are summarized in table.2 
Fig: 6 show the drug conc. in plasma and brain after 
intranasal administration of hybrid nanoparticles HN4. 
The Cmaxwas achieved in 5min in brain and the Cmax was 
found to be 3230,   but in plasma it has taken 30min to 
achieve Cmax. The Cmax in plasma was found to be 
1298ng. The AUC(Brain) and AUC(Plasma) ratio as 2.996, 
which shows, the high distribution into brain than 
plasma can be achieved with hybrid nanoparticles 
having higher conc. of chitosan. It shows hybrid 
nanoparticles target the brain rather than plasma, when 
chitosan was used in twice amount of lipid. Because the 
chitosan has the mucoadhesive property which enhanced 
the residence time of formulation in the nasal cavity. 
The DTE was found to be 3.698. The study shows that 
formulation HN4 achieves the highest conc. in brain 
followed by HN2 then by i.v. 
The pharmacokinetic parameter after i.v. and intranasal 
administration of carbamazepine in plasma and brain are 
given in table 4 and brain to plasma ratio at different 
time point is shown in fig.7. 
 
 
Figure 6: Showing the plasma brain profile of formulation HN4 the conc. Of drug ng/ml in the plasma and brain after 
intranasal administration of formulation n=3 SEM unpaired ANOVA, ** represents a significant difference, p<0.05. 
Table 4: Showing pharmacokinetic parameter after i.v. and intranasal administration of carbamazepine 
Formulation  Organ/tissue Cmax Tmax AUC120min DTE 
 
i.v. 
Blood 1199ng 5min 110.51 µgml
-1
 min
-1    
 ------ 
Brain 1357 ng 30min 78.96 µgml
-1
 min
-1
 
 
HN2 Nasal 
Blood 1230ng 45 min 65.850 µgml
-1
 min
-1
 2.566 
Brain 2730ng  5min 120.740 µgml
-1
 min
-1
 
 
HN4 Nasal 
Blood 1298ng
 
5min 46.592µgml
-1
 min
-1
 3.69 
Brain 3220ng  45 min 123.05µgml
-1
 min
-1
 
 
 
Figure 7: Showing a comparative Brain to Plasma Ratio of i.v. and intransal, HN2 and HN4 at different time point 
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CONCLUSION 
The study confirmed that there is direct nose to brain 
delivery of carbamazepine which can be advantageous 
for other CNS active drugs which shows side effects by 
oral or intravenous route. The results also show that the 
method of preparation was found suitable for making 
hybrid nanoparticles. The study also shows that Hybrid 
nanoparticles can be applied for acute conditions. It can 
be concluded that hybrid nanoparticles have a good 
targeting efficiency to the brain from nasal route. 
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